--- title: "Bel Fuse | 8-K: FY2026 Q2 Revenue: USD 210.69 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/294260897.md" datetime: "2026-07-29T20:55:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294260897.md) - [en](https://longbridge.com/en/news/294260897.md) - [zh-HK](https://longbridge.com/zh-HK/news/294260897.md) generator: "portal-rs" --- # Bel Fuse | 8-K: FY2026 Q2 Revenue: USD 210.69 M Revenue: As of FY2026 Q2, the actual value is USD 210.69 M. EPS: As of FY2026 Q2, the actual value is USD 1.89. EBIT: As of FY2026 Q2, the actual value is USD 39.56 M. #### Net Sales Bel Fuse Inc. reported net sales of $210.7 million in Q2-26, marking a 25.1% increase from $168.3 million in Q2-25. For the first half of 2026, net sales reached $389.176 million, up from $320.537 million in the first half of 2025. #### Gross Profit and Margin The gross profit margin for Bel Fuse Inc. was 39.9% in Q2-26, an increase from 38.7% in Q2-25. For the first half of 2026, the gross profit margin was 39.5%, compared to 38.7% in the first half of 2025. #### Operational Costs Research and development costs were $9.006 million in Q2-26, up from $8.104 million in Q2-25. Selling, general, and administrative expenses were $36.285 million (17.2% of net sales) in Q2-26, which is a decrease from 18.4% of net sales in Q2-25. #### Income from Operations Income from operations was $38.419 million (18.2% of net sales) in Q2-26, compared to $29.860 million (17.7% of net sales) in Q2-25. For the first half of 2026, income from operations was $62.085 million (16.0% of net sales), compared to $54.883 million (17.1% of net sales) in the first half of 2025. #### Net Earnings Attributable to Bel Fuse Shareholders GAAP net earnings attributable to Bel Fuse Inc. shareholders were $25.5 million in Q2-26, compared to $26.9 million in Q2-25. Non-GAAP net earnings attributable to Bel Fuse Inc. shareholders were $39.1 million in Q2-26, an increase from $21.0 million in Q2-25. #### Adjusted EBITDA Adjusted EBITDA was $48.9 million (23.2% of sales) in Q2-26, compared to $35.2 million (20.9% of sales) in Q2-25. For the first half of 2026, Adjusted EBITDA was $83.346 million (21.4% of sales), compared to $66.096 million (20.6% of sales) in the first half of 2025. #### Cash and Debt Management Bel Fuse Inc. raised $441.6 million in net proceeds from an equity offering and used $197.5 million to pay down debt. #### Cash Flow from Operating Activities Net cash provided by operating activities was $31.762 million for the first half of 2026, compared to $28.864 million for the first half of 2025. #### Cash and Cash Equivalents Cash and cash equivalents at the end of Q2-26 totaled $306.106 million, an increase from $57.800 million at the beginning of the year. #### Segment Revenue - **Aerospace, Defense & Rugged Solutions**: Sales for this segment were $110.457 million in Q2-26, an increase of 20.3%. The gross margin was 41.1%, representing a decrease of 30 basis points. - **Industrial Technology & Data Solutions**: Sales for this segment were $100.228 million in Q2-26, an increase of 31.1%. The gross margin was 38.8%, an increase of 220 basis points. #### Operational Milestones DataMate completed its facility transition and ERP conversion. Bel Fuse Inc.’s Slovakia site achieved defense-manufacturer qualification to support Enercon integration and European expansion. #### Outlook / Guidance Bel Fuse Inc. projects third-quarter 2026 sales to be between $205 million and $225 million, assuming current market conditions persist. The company also anticipates a gross margin of 39% to 41% for Q3-26. These projections are supported by healthy bookings, momentum in end markets, an expanded European footprint, and a strong balance sheet. ### Related Stocks - [BELFA.US](https://longbridge.com/en/quote/BELFA.US.md) ## Related News & Research - [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md) - [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md) - [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md) - [HF Sinclair announces Q3 2026 dividend of R$ 1.81 per unit](https://longbridge.com/en/news/298317474.md) - [Cummins announces Q3 2026 dividend of R$ 0.14 per unit for BRC1MIBDR009](https://longbridge.com/en/news/298325727.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**